Industry Veteran with Deep Scientific Expertise Will Focus on the
Execution of Business Development Strategy
RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--Sep. 11, 2018--
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical
company, today announced that Jones “Woody” Bryan, Ph.D. has been
appointed as Senior Vice President of Business Development. Dr. Bryan is
a seasoned industry veteran who brings to UroGen over 25 years of
experience driving growth across organizations with his diverse track
record of product and technology licensings and M&A negotiations and
transactions. Dr. Bryan will focus on the integration of corporate
strategy and business development to assess potential partnerships and
bolster UroGen’s product portfolio.
“We are very excited to have someone of Woody’s caliber join our team
and help us fully realize the burgeoning opportunity of lead drug
candidates, UGN-101 and UGN 102 and our RTGel™ technology platform, to
potentially provide novel therapies for patients worldwide,” said Ron
Bentsur, Chief Executive Officer of UroGen. “Woody’s extensive
experience in strategy and business development, as well as his
long-standing relationships with key industry players, will be important
as we focus on executing our business development strategy.”
“I believe UroGen has the transformative science, encouraging data,
dedicated team of industry veterans, and strong financial position to
change the treatment paradigm in uro-oncology,” said Dr. Bryan. “I look
forward to helping more patients and creating added value for
shareholders by building on UroGen’s existing foundation with new,
innovative partnerships.”
Dr. Bryan previously served as SVP of Business Development at Sucampo
Pharmaceuticals, Inc., where he spearheaded the business development
effort for its recent acquisition by Mallinckrodt Pharmaceuticals for
$1.2 billion earlier this year. In this role, he also led the evaluation
of several in-licensing opportunities and acquisition of multiple
assets. Prior to joining Sucampo, Dr. Bryan was SVP of Business
Development at Lupin Pharmaceuticals, Inc. His previous roles include VP
of Business Development, Licensing at Supernus Pharmaceuticals, Inc. and
VP of Business Development, Licensing and Project Management at Shire
Laboratories, Inc. (a Division of Shire Pharmaceuticals Group). He is
currently a Board Member of Afecta Pharma and a Board Member and past
Chairman of Clemson University’s Spiro Institute of Entrepreneurial
Leadership and Innovation. Dr. Bryan holds a B.S. in zoology from
Clemson University, a Ph.D. in pharmaceutical sciences from the Medical
University of South Carolina, and an Executive Management Certificate
from the University of North Carolina at Chapel Hill Kenan-Flagler
School of Business.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is
a clinical-stage biopharmaceutical company developing advanced
non-surgical treatments to address unmet needs in the field of urology,
with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs. UroGen’s
sustained release technology is designed to enable longer exposure of
the urinary tract tissue to medications, making local therapy a
potentially more effective treatment option. UroGen’s lead product
candidates, UGN-101 (mitomycin gel for urothelial instillation),
formerly known as MitoGel®, and UGN-102 (mitomycin gel for
intravesical instillation), formerly known as VesiGel™, are designed to
potentially remove tumors by non-surgical means and to treat several
forms of non-muscle invasive urothelial cancer, including low-grade
upper tract urothelial carcinoma and bladder cancer, respectively.
UroGen is headquartered in Ra’anana, Israel with U.S. headquarters
in New York.
Forward Looking Statements
This press release contains
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995, including with respect to
regulatory approval and commercial prospects of the product candidates
in UroGen Pharma’s pipeline, UroGen Pharma’s ability to change the
treatment paradigm in uro-oncology, UroGen Pharma’s ability to establish
new, innovative partnerships, and the general effects of Dr. Bryan
joining UroGen Pharma, which statements are subject to a number of
risks, uncertainties and assumptions, including, but not limited to: the
timing and success of clinical trials and potential complications
thereof; the ability to obtain and maintain regulatory approval; the
labeling for any approved product; the scope, progress and expansion of
developing and commercializing UroGen Pharma’s product candidates; the
size and growth of the market(s) therefor and the rate and degree of
market acceptance thereof vis-à-vis alternative therapies; and UroGen
Pharma’s ability to attract or retain key management, members of the
board of directors and personnel. In light of these risks and
uncertainties, and other risks and uncertainties that are described in
the Risk Factors section of the final prospectus for UroGen Pharma’s
public offering of securities in the United States filed with
the SEC on January 22, 2018 and other filings that UroGen Pharma makes
with the SEC from time to time (which are available at http://www.sec.gov),
the events and circumstances discussed in such forward-looking
statements may not occur, and UroGen Pharma’s actual results could
differ materially and adversely from those anticipated or implied
thereby. Any forward-looking statements speak only as of the date of
this press release and are based on information available to UroGen
Pharma as of the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180911005421/en/
Source: UroGen Pharma Ltd.
UROGEN:
Kate Bechtold, 914-552-0456
Director, Corporate
Communications & Investor Relations
Kate.Bechtold@urogen.com
